Paroxetine + Tamoxifen

Paroxetine and tamoxifen represent a drug combination with potential interactions. Tamoxifen is a selective estrogen receptor modulator (SERM) used in breast cancer treatment, while paroxetine is an antidepressant that belongs to the selective serotonin reuptake inhibitor (SSRI) class. The key concern with this combination is that paroxetine is a strong inhibitor of the cytochrome P450 2D6 (CYP2D6) enzyme, which is responsible for converting tamoxifen to its active metabolite, endoxifen. This interaction can lead to reduced conversion of tamoxifen to endoxifen, potentially diminishing tamoxifen's therapeutic efficacy. Clinical evidence on this interaction is conflicting: A 2010 study found that paroxetine use during tamoxifen treatment was associated with an increased risk of death from breast cancer. However, a larger 2015 study involving 16,887 breast cancer survivors did not observe a statistically significant increased risk of subsequent breast cancer with concurrent tamoxifen and antidepressant use, including paroxetine. Despite the more recent reassuring evidence, many clinicians still exercise caution. Recommendations often include avoiding strong CYP2D6 inhibitors (including paroxetine, fluoxetine, and bupropion) in women taking tamoxifen. Alternative antidepressants that are weak or moderate CYP2D6 inhibitors may be preferred. For postmenopausal women, switching from tamoxifen to an aromatase inhibitor might be considered if a strong CYP2D6 inhibitor cannot be avoided. If antidepressants are used solely for managing tamoxifen-related hot flashes, non-antidepressant alternatives like gabapentin may be considered. This drug combination is classified as having potentially significant clinical interactions, with some sources recommending avoiding it when possible.